• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, August 22, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Increase in conservative management of low-risk prostate cancer

Bioengineer by Bioengineer
February 11, 2019
in Cancer
Reading Time: 1 min read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Bottom Line: National guidelines in 2010 began advocating conservative management of low-risk prostate cancer with active surveillance or watchful waiting (AS/WW) as an alternative to radiation to the treat the prostate or surgery to remove the entire prostate. This study examined trends in the management of localized prostate cancer among 165,000 men from 2010 to 2015 using data from a national database of cancer statistics. Use of AS/WW for men with low-risk localized prostate cancer increased from 14.5 percent in 2010 to 42 percent in 2015, becoming the most common management approach. Use of AS/WW increased among men with intermediate-risk disease and remained stable among those with high-risk disease. Surgery to remove the entire prostate declined among men with low-risk disease but increased among patients with higher-risk disease. A limitation of the study is the lack of data on AS/WW compliance.

Authors: Brandon A. Mahal, M.D., Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Boston, and coauthors.

(doi:10.1001/jama.2018.19941)

Editor’s Note: The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

###

Want to embed a link to this study in your story? This full-text link will be live at the embargo time: http://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2018.19941

Media Contact
Victoria Warren

[email protected]

Tags: Medicine/HealthProstate Cancer
Share12Tweet7Share2ShareShareShare1

Related Posts

New Insights into the Cumulative HBsAg/HBV DNA Ratio in Immune-Tolerant Hepatitis B Patients

New Insights into the Cumulative HBsAg/HBV DNA Ratio in Immune-Tolerant Hepatitis B Patients

August 22, 2025
blank

Anti-PD-1 Boosts Gastric Cancer with Hepatitis B

August 22, 2025

Innovative Tool Uncovers Key Targets to Enhance CAR NK Cell Therapy Effectiveness

August 22, 2025

Nomogram Predicts Lung Cancer Immunotherapy Success

August 22, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Molecules in Focus: Capturing the Timeless Dance of Particles

    141 shares
    Share 56 Tweet 35
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    114 shares
    Share 46 Tweet 29
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    81 shares
    Share 32 Tweet 20
  • Modified DASH Diet Reduces Blood Sugar Levels in Adults with Type 2 Diabetes, Clinical Trial Finds

    60 shares
    Share 24 Tweet 15

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Brain Area 46: The Hub of Emotion Regulation in Marmosets

New Insights into the Cumulative HBsAg/HBV DNA Ratio in Immune-Tolerant Hepatitis B Patients

Anti-PD-1 Boosts Gastric Cancer with Hepatitis B

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.